thalidomide has been researched along with Orthomyxoviridae Infections in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Orthomyxoviridae Infections: Virus diseases caused by the ORTHOMYXOVIRIDAE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Swine-origin influenza A virus has caused pandemics throughout the world and influenza A is regarded as a serious global health issue." | 1.36 | Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide. ( Harada, Y; Hashimoto, Y; Hatakeyama, D; Ishikawa, M; Itamura, S; Iwai, Y; Kuzuhara, T; Motoshima, K; Odagiri, T; Sei, Y; Sugita, K; Takahashi, H; Tashiro, M; Yamaguchi, K, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, H | 1 |
| Shi, X | 1 |
| Ju, D | 1 |
| Huang, H | 1 |
| Wei, W | 1 |
| Dong, X | 1 |
| Iwai, Y | 1 |
| Takahashi, H | 1 |
| Hatakeyama, D | 1 |
| Motoshima, K | 1 |
| Ishikawa, M | 1 |
| Sugita, K | 1 |
| Hashimoto, Y | 1 |
| Harada, Y | 1 |
| Itamura, S | 1 |
| Odagiri, T | 1 |
| Tashiro, M | 1 |
| Sei, Y | 1 |
| Yamaguchi, K | 1 |
| Kuzuhara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for thalidomide and Orthomyxoviridae Infections
| Article | Year |
|---|---|
Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Inflammation Mediators; Influenza A Virus, H1N1 Subtype; Lung Inj | 2014 |
Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Inflammation Mediators; Influenza A Virus, H1N1 Subtype; Lung Inj | 2014 |
Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Inflammation Mediators; Influenza A Virus, H1N1 Subtype; Lung Inj | 2014 |
Anti-inflammatory effect of thalidomide on H1N1 influenza virus-induced pulmonary injury in mice.
Topics: Animals; Anti-Inflammatory Agents; Inflammation Mediators; Influenza A Virus, H1N1 Subtype; Lung Inj | 2014 |
Anti-influenza activity of phenethylphenylphthalimide analogs derived from thalidomide.
Topics: Animals; Antiviral Agents; Cell Line; DNA-Directed RNA Polymerases; Dogs; Humans; Influenza A virus; | 2010 |